Literature DB >> 10923673

Synaptic localization of p39, a neuronal activator of cdk5.

S Humbert1, L M Lanier, L H Tsai.   

Abstract

The expression and kinase activity of cyclin dependent kinase 5 (cdk5) parallels the extent of neuronal differentiation. Cdk5 activity has been shown to be required for neurite outgrowth, cortical lamination and the overall development of the nervous system. p35 was identified as the first regulatory activator of cdk5 whose presence is required for cdk5 activation. p39 is a homolog of p35, and the only one identified in mammals thus far. We show here that p39 expression is mainly postnatal. In addition, we provide evidence for the presence of p39 at synaptic junctions through co-fractionation experiment, electron microscopy and immunostaining. The temporal and spatial expression of p39 indicate a possible role of the p39/cdk5 kinase at the synapse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923673     DOI: 10.1097/00001756-200007140-00030

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

Review 1.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

2.  p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment.

Authors:  J Ko; S Humbert; R T Bronson; S Takahashi; A B Kulkarni; E Li; L H Tsai
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

3.  p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.

Authors:  Wenqi Li; Megan E Allen; Yanfang Rui; Li Ku; Guanglu Liu; Andrew N Bankston; James Q Zheng; Yue Feng
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

4.  Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease.

Authors:  Kai-Hui Sun; Hyoung-gon Lee; Mark A Smith; Kavita Shah
Journal:  Mol Biol Cell       Date:  2009-09-23       Impact factor: 4.138

5.  Targeted gene mutation of E2F1 evokes age-dependent synaptic disruption and behavioral deficits.

Authors:  Jenhao H Ting; David R Marks; Stephanie S Schleidt; Joanna N Wu; Jacob W Zyskind; Kathryn A Lindl; Julie A Blendy; R Christopher Pierce; Kelly L Jordan-Sciutto
Journal:  J Neurochem       Date:  2014-02-12       Impact factor: 5.372

6.  The cyclin-dependent kinase 5 activators p35 and p39 interact with the alpha-subunit of Ca2+/calmodulin-dependent protein kinase II and alpha-actinin-1 in a calcium-dependent manner.

Authors:  Rani Dhavan; Paul L Greer; Maria A Morabito; Lianna R Orlando; Li-Huei Tsai
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35.

Authors:  Elias Utreras; Akira Futatsugi; Parvathi Rudrabhatla; Jason Keller; Michael J Iadarola; Harish C Pant; Ashok B Kulkarni
Journal:  J Biol Chem       Date:  2008-12-02       Impact factor: 5.157

8.  Sp1 and Sp3 regulate transcription of the cyclin-dependent kinase 5 regulatory subunit 2 (p39) promoter in neuronal cells.

Authors:  Alvaro Valin; Julie D Cook; Sarah Ross; Christi L Saklad; Grace Gill
Journal:  Biochim Biophys Acta       Date:  2009-03

9.  p39, the primary activator for cyclin-dependent kinase 5 (Cdk5) in oligodendroglia, is essential for oligodendroglia differentiation and myelin repair.

Authors:  Andrew N Bankston; Wenqi Li; Hui Zhang; Li Ku; Guanglu Liu; Filomena Papa; Lixia Zhao; James A Bibb; Franca Cambi; Seema K Tiwari-Woodruff; Yue Feng
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

10.  p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide.

Authors:  Kathleen I Seyb; Sabah Ansar; Guibin Li; Jennifer Bean; Mary L Michaelis; Rick T Dobrowsky
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.